Innoviva Inc. – Underwriting Agreements

NASDAQ: INVA
Share price (8/10/26): $20.68
Market cap (8/10/26): $1.494 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Underwriting Agreements Filter

from 8-K 32 pages Note Purchase Agreement Dated April 17, 2014 Among Theravance, Inc., Laba Royalty Sub LLC and the Purchaser Named Herein $450,000,000 Laba Pharmasm 9.0% Fixed Rate Term Notes Due 2029

from 8-K 42 pages Theravance, Inc. (A Delaware Corporation) 2.125% Convertible Subordinated Notes Due 2023 Underwriting Agreement

from S-3ASR 35 pages Theravance, Inc. (A Delaware Corporation) [·]% Convertible Subordinated Notes Due 2023 Underwriting Agreement

from 8-K 30 pages Theravance, Inc. (A Delaware Corporation) 7,500,000 Shares of Common Stock Underwriting Agreement

from 8-K 26 pages Theravance, Inc. (A Delaware Corporation) 3% Subordinated Convertible Notes Due 2015 Purchase Agreement

from S-3ASR 27 pages Theravance, Inc. (A Delaware Corporation) • % Subordinated Convertible Notes Due 2015 Purchase Agreement

from S-3ASR 25 pages Theravance, Inc. (A Delaware Corporation) 4,600,000 Shares of Common Stock Purchase Agreement

from S-1/A 29 pages Theravance, Inc. (A Delaware Corporation) [ • ] Shares of Common Stock Purchase Agreement